| Literature DB >> 31587001 |
Supatat Chumnumwat1, Zen Huat Lu2, Chonlaphat Sukasem3, Michael David Winther4,5, Francis R Capule6, Asma A Apos Tiyah Abdul Hamid7, Bibek Bhandari8, Usa Chaikledkaew1, Noppadol Chanhom9, Soranun Chantarangsu10, Angkana Charoenyingwattana11, Tong Thi Hang12, Tin Maung Hlaing13, Kyaw Soe Htun13, Jiraphun Jittikoon9, Ly Le12,14, Surakameth Mahasirimongkol15, Dzul Azri Mohamed Noor16, Jesus Shrestha8, Lakkana Suwannoi1, Pramote Tragulpiankit1, Saowalak Turongkaravee1, Sukanya Wattanapokayakit15, Phonepadith Xangsayarath17, Rika Yuliwulandari18, Shamsul Mohd Zain19, Wasun Chantratita20.
Abstract
Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.Keywords: Drug-induced liver injury; Pharmacogenomics; Southeast Asia; Stevens-Johnson syndrome; Toxic epidermal necrolysis
Mesh:
Year: 2019 PMID: 31587001 DOI: 10.1159/000502916
Source DB: PubMed Journal: Public Health Genomics ISSN: 1662-4246 Impact factor: 2.000